Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP|June 10, 2023
National Cancer Registry of Pakistan: First Comprehensive Report of Cancer Statistics 2015-2019Aamer Ikram, Shahid Pervez, Muhammad Tahir Khadim, et al.
Brazilian Journal of Biology = Revista Brasleira De Biologia|September 29, 2021
Isolation and characterization of bacteria residing in the oral, gut, and fecal samples of different pheasant speciesM Mushtaq, S M Bukhari, S Ahmad, et al.
Current Problems in Cancer|September 27, 2021
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancerA Jalali, G Gard, S Banks, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world characteristics and outcomes of patients with BRAF<sup>V600E</sup>-mutant metastatic colorectal cancer in Australia: the COALA projectN Hitchen, H-L Wong, R Wong, et al.
ESMO Open|March 2, 2023
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastasesJ R Hecht, S S Raman, A Chan, et al.
Journal of Cancer Research and Clinical Oncology|August 22, 2023
Detection of metastases using circulating tumour DNA in uveal melanomaAaron B Beasley, Daniël P de Bruyn, Leslie Calapre, et al.
Oncotarget|November 3, 2015
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanomaElin S Gray, Helen Rizos, Anna L Reid, et al.
Nature Medicine|January 8, 2025
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trialReinhard Dummer, Caroline Robert, Richard A Scolyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in CombinationAna Arance, Luis de la Cruz-Merino, Teresa M Petrella, et al.
The Lancet. Oncology|February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 studyReinhard Dummer, Jun Guo, Jason J Luke, et al.
Pageof 7